A Pivotal Spring Agenda for CorMedix Investors

CorMedix enters a pivotal period with March investor conferences, Q4 earnings, a $75M buyback plan, and key 2026 clinical readouts for REZZAYO and DefenCath.

The coming months present a series of critical events for CorMedix Inc., setting the stage for a period of heightened investor focus. The company’s calendar is packed with strategic presentations, financial disclosures, and key clinical updates that collectively shape its near-term trajectory.

Strategic Dialogues and Financial Disclosure

Management is scheduled to engage with the investment community at several high-profile conferences in March. This series of events begins with the Leerink Partners Global Healthcare Conference on March 10. The following day, March 11, features participation in the Citizens Life Sciences Conference. These are complemented by one-on-one meetings scheduled for the Barclays Global Healthcare Conference on March 12.

Separately, the firm is anticipated to release its latest quarterly financial results toward the end of the month. Current market expectations point to a publication date around March 24, though announcements on March 30 or 31 remain distinct possibilities. These figures will provide essential insights into the company’s financial health and the commercial progress of its product, DefenCath.

Capital Allocation and Pipeline Catalysts

In a significant move regarding capital strategy, the board has recently authorized a new share repurchase initiative. This program permits the company to buy back up to $75 million of its own equity through the end of 2027. Initial repurchases under this authorization could be executed as early as the first quarter of 2026.

Concurrently, important clinical milestones are approaching on the development timeline. Topline results from the Phase III "ReSPECT" trial for REZZAYO are expected in the second quarter of 2026. This study evaluates the drug for the prevention of invasive fungal infections in adult patients who have undergone blood or bone marrow transplants. Given that REZZAYO is already approved for the treatment of candidemia, a positive outcome in this trial would substantially broaden its commercial potential.

Further development work is also advancing for DefenCath. Investigational efforts are focusing on its application in total parenteral nutrition (TPN) and in pediatric hemodialysis settings. The confluence of these financial and clinical updates, starting with the Leerink conference appearance on March 10, offers shareholders a dense period of material information.